25-NSE ·Filed May 18, 2026

SYBX

SYNLOGIC, INC.
BEARISH
Impact 7/10
Horizonimmediate Processed4mo ago SEC0001354457-26-000470
Notable filing: 25-NSE
Actionable Insight ▼ Bearish

The delisting is already priced in as the stock has been suspended and trading OTC since January 21, 2026. This 25-NSE finalizes the deregistration process with the SEC. Traders should watch for any subsequent steps such as a potential voluntary deregistration under Section 12(g) or going-private transaction, which would further reduce liquidity and transparency.

DirectionBearish
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
SYBX ▲ +82.58% at T+60d
SHORT call ✗ call lost -82.58% · α vs SPY -77.72% · entry $0.6600 → $1.21
Entry anchored
May 18, 2026
via day open
T+1d
0.00%
call 0.00% · α -0.65%
$0.6600
settled 5mo ago
T+5d
0.00%
call 0.00% · α +1.62%
$0.6600
settled 4mo ago
T+20d
-6.82%
call +6.82% · α +8.40%
$0.6150
settled 4mo ago
T+60d
+82.58%
call -82.58% · α -77.72%
$1.21
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Nasdaq has finalized the delisting of Synlogic, Inc. (SYBX) common stock, effective May 28, 2026, following a withdrawal of the company's appeal and a January 2026 suspension. The stock has already been trading OTC since its suspension on January 21, 2026, making this 25-NSE filing a formal deregistration step with limited incremental trading impact.

Key Facts

  • Nasdaq Staff determined Synlogic no longer qualified for listing under Listing Rule 5101, with initial notification on November 21, 2025.
  • Synlogic withdrew its appeal on January 16, 2026, and the Panel's decision to suspend the stock from the Exchange took effect on January 21, 2026.
  • Delisting becomes final at the opening of trading on May 28, 2026 — formal removal from Nasdaq registration.
  • Stock has been trading OTC since January 21, 2026 suspension; this filing is the final deregistration step.

Financial Impact

Complete loss of Nasdaq listing and registration for SYBX common stock; no transaction value or financial details provided in the filing.

liquiditymarket_accesstrading_venue

Risk Factors

  • Further reduced liquidity and institutional ownership as the stock is removed from all national exchange trading.
  • Potential risk of a going-private transaction or additional deregistration, eliminating public reporting obligations and further limiting shareholder exit options.
  • Possible downward re-rating as the company loses Nasdaq qualification, which may affect any remaining analyst coverage or investor interest.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
25-NSE Filing (Primary)0001354457-26-000470
Document: 0001354457-26-000470-index-headers.html0001354457-26-000470
Document: 0001354457-26-000470-index.html0001354457-26-000470
Document: 0001354457-26-000470.txt0001354457-26-000470
3 reports for SYBX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SYBX — sortable, filterable
TypeNow
Jul 29, 2026
9w ago
425 / 8-K
BEARISH ★ 7/10
$1.12 $1.22▼ −8.93%▼ −3.91%$1.11 (+0.89%)
May 18, 2026
19w ago
25-NSE
BEARISH ★ 7/10
$0.6600 $0.6150▲ +6.82%▲ +8.40%$1.11 (−68.18%)
Apr 30, 2026
22w ago
10-K/A
NEUTRAL ★ 2/10
$0.6050 $0.6900▲ +14.05%▲ +8.78%$1.11 (+83.47%)
Showing 3 of 3

US Market Status

Market Closed — Opens Mon (65h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access